Key points are not available for this paper at this time.
Abstract Aims The present study aims to determine the effects of sodium‐glucose cotransporter 2 (SGLT‐2) inhibitors on the serum uric acid (SUA) levels of patients with type 2 diabetes mellitus (T2DM) in Asia. Methods PubMed, CENTRAL, Embase and Cochrane Library databases were searched for randomized controlled trials of SGLT‐2 inhibitors in patients with T2DM up to 15 July 2021, without language or date restrictions. Results In total, 19 high‐quality studies (4218 participants) were included in the present network meta‐analysis. All of the included SGLT‐2 inhibitors (empagliflozin, dapagliflozin, canagliflozin, ipragliflozin, luseogliflozin and tofogliflozin) significantly decreased SUA levels compared with those of the control total standard mean difference –0.965, 95% CI (−1.029, −0.901), p = .000, I 2 = 98.7% in patients with T2DM. Subgroup analysis and meta‐regression showed that the combined analysis of different inhibitors might lead to heterogeneity of the results. Therefore, among the SGLT‐2 inhibitors, the results of the subsequent network meta‐analysis revealed that luseogliflozin and dapagliflozin ranked the highest in terms of lowering SUA levels among the SGLT‐2 inhibitors. Moreover, the network meta‐analysis declared that luseogliflozin (1 and 10 mg) and dapagliflozin (5 mg) led to a superior reduction in SUA in patients with T2DM. Conclusions SGLT‐2 inhibitors could significantly reduce SUA levels in patients with T2DM, particularly luseogliflozin (1 and 10 mg) and dapagliflozin (5 mg) possess the best effects. Therefore, SGLT‐2 inhibitors look extremely promising as an antidiabetes treatment option in patients with T2DM with high SUA.
Hu et al. (Fri,) studied this question.